Patients with biallelic variants in breast cancer 2 (BRCA2, also known as FANCD1) and partner and localizer BRCA2 (PALB2, also known as FANCN) may present with characteristic FA developmental abnormalities and classically develop acute myeloid leukemias and embryonal tumors including medulloblastoma, neuroblastoma, and Wilms tumors. This evidence concerns the gene BRCA2 and Nephroblastoma.